Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners
Linkedbio Partnering: Linkedbio Analysis:
Lingmed Innovative Project Recommendation No.429European Innovative Gynecological Diseases Project Treating Uterine Fibroids Seeking partner in Greater China (LMP2797)
Project ID：LMP2797
Company ID: LMC5000554
Epidemiology of Uterine Leiomyomas
Current Status of Uterine Fibroid Treatment
Project Description：Novel non-steroidal selective progesterone-receptor modulator
Indications：Uterine fibroids, heavy menstrual bleeding, and endometriosis
Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.428European Innovative Skin Diseases Project Seeking partner in Greater China (LMP1452)
Project ID：LMP1452
Company ID: LMC5000606
Project Description：Highly selective C5aR inhibitor; Best-in-Class immune-modulator
Indications：Hidradenitis Suppurativa (HS) 、 Chronic Spontaneous Urticaria (CSU)、other immuno-dermatology
Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.427Overseas Innovative Skin Disease Project — Treating Keratoderma and Itching
Project ID：LMP1949、LMP1950
Company ID: LMC5001490
Project Description：
Indications：
Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.426European Innovative Drug Delivery Project Treating Multiple emergency crisis Seeking partner in Greater China (LMP2799)
Project ID：LMP2799
Company ID: LMC5001768
Project Description：Needle-free auto-injector; Gold standard molecule + LMP2799 needle-free auto-injector = Patented prescription drug; 505(b)(2); for emergency use by non-medical professionals
Indications：Multiple critical conditions, such as seizures, adrenal crisis, anaphylactic shock, severe asthma crisis, severe migraine-hemicrania, chronic rheumatoid arthritis, opioid overdose
Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.425European Innovative Skin tumor Project Seeking partner in Greater China (LMP2804)
Project ID：LMP2804
Company ID: LMC5001773
Project Description：Non-invasive and non-toxic gold nanoparticle photothermal therapy, which physically destroys tumors by heat; Class III medical device
Indications：Skin tumors
Project Description, Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.424US Innovative Oncology Project —— Treating Head & Neck Cancer/Glioma Seeking partner in Greater China (LMP2803)
Project ID：LMP2803
Company ID: LMC5001772
Project Description：Metalloporphyrins; New class radioprotectant & radiosensitizer; Platform drug for chemoradiation with potential for treating multiple cancers; Dual mechanism of action; FDA Breakthrough Therapy Designation
Indications：Head and neck cancer, anal/rectal cancer, high-grade glioma, ovarian cancer, and other solid tumors
Project Description, Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.423US Innovative Respiratory Disease Project –Treating Acute Respiratory Viral Infection-Seeking partner in Greater China (LMP2802)
Project ID：LMP2802
Company ID: LMC5001771
Epidemiology of RSV Infection
Current Status of RSV Infection Treatment
Indications：RSV Infection
Project Description, Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Newsletter Dec 2025In this month summary, Lingmed recommends
Lingmed asset recommendation 1：European Innovative Oncology Project–Treating Platinum-Resistant Ovarian Cancer
Lingmed asset recommendation 2：Overseas Innovative Anti-Infective Project–Treating Multidrug-Resistant Gram-Negative Bacterial Infections
Lingmed asset recommendation 3：US Innovative CNS Project–Treating Drug-Resistant Focal Onset Seizures
The Oct & Nov 2025 overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Q4 2025 financial Summary of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Innovative Project Recommendation No.420US Innovative CNS Project – Treating Drug-Resistant Focal Onset Seizures Seeking partner in Greater China (LMP2800)
Project ID：LMP2800 Company ID: LMC5001769
Epidemiology of Drug-Resistant Focal Epilepsy
Current Status of Focal Epilepsy Treatment
Indications：Drug resistant adult focal onset seizures
Project Description, Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.419Innovative Anti-Infective Project –Treating Multidrug-Resistant Gram-Negative Bacterial Infections Seeking partner in Greater China (LMP2801)
Project ID：LMP2801, Company ID: LMC5001770
Acinetobacter baumannii introduction
HAP/VAP infection status
Indications：Hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC)
Project Description, Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.418European Innovative Oncology Project –Treating Platinum-Resistant Ovarian Cancer Seeking partner in Greater China (LMP2798)
Project ID：LMP2798, Company ID:LMC5001767
Epidemiology of Platinum-Resistant Ovarian Cancer（PROC）
Current Status of PROC Treatment
Project Description：Platinum-resistant ovarian cancer (patients who have previously received ≥4 lines of chemotherapy, MSLN positive); other MSLN positive solid tumors
Indications：CD47/MSLN bispecific antibody
Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.417US Innovative Treating Alzheimer’s Disease Seeking partner in Greater China (LMP2791)
Project ID：LMP2791；Patented AI-powered target discovery platform
Project Description：Humanized monoclonal antibody selectively targets toxic Aβ oligomers
Indications：Mild cognitive impairment (MCI) caused by Alzheimer's disease (AD)
Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Lingmed Innovative Project Recommendation No.416European Innovative Respiratory Diseases Project –Treating Asthma Seeking partner in Greater China (LMP2796)
Project ID: LMP2796
Epidemiology of Asthma
Current Status of Asthma Treatment
Project Description：Encodes interferon λ (IFNλ), targeting the viral triggers of acute asthma attacks; a new preventive drug for moderate to severe asthma; mRNA therapy
Indications，Development Phase，Administration Route，Partnership Goal，Company Overview, Project Highlights......
Lingmed Innovative Project Recommendation No.415European Innovative Autoimmune/Inflammation Project – Treating Rheumatoid Arthritis Seeking Partners in China (LMP1278)
Project ID: LMP1278
Epidemiology of Rheumatoid Arthritis
Current Status of Rheumatoid Arthritis Treatment
Project Description：Novel biased melanocortin receptor agonists; MC1R & MC3R agonists, activating the ERK1/2 pathway; First-in-Class；small molecule
Indications，Development Phase，Administration Route，Partnership Goal，Company Overview, Project Highlights......
Lingmed Innovative Project Recommendation No.414European Innovative Autoimmune Disease Project – Treatment for Rheumatoid Arthritis (RA) Seeking Partners in China (LMP2795)
Project ID: LMP2795
Epidemiology of Rheumatoid Arthritis
Current Treatment Status of Rheumatoid Arthritis
Lingmed Recommendation – Rheumatoid Arthritis Project：Project Description，Indications，Development Phase，Administration Route，Partnership Goal，Company Overview, Project Highlights......
Lingmed Newsletter Oct 2025In this month summary, Lingmed recommends
Lingmed asset recommendation 1：European innovative immuno-oncology project treating hematological tumors
Lingmed asset recommendation 2：European innovative immuno-oncology project treating GARP-positive solid tumors
The Sep 2025 overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Q3 2025 financial analysis of global biopharmaceuticals market——M&A report by Biotechgate data analysis team
Lingmed Innovative Project Recommendation No.412European innovative immuno-oncology project seeks global collaboration in the treatment of hematological tumors (LMP2789)
Project ID: LMP2789
Project Description: Fully human, defucosylated anti-ROR1 monoclonal antibody (IgG1 antibody)
Project Phase: Phase 0 completed; Phase 1 planned for 2026 (B-CLL)
Indications: B-cell chronic lymphocytic leukemia/mantle cell lymphoma (B-CLL/MCL); chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Partnering needs: Actively seeking global strategic partners for co-development, licensing, or equity investment
Company Profile, Project Background, Project Highlights......
Lingmed Innovative Project Recommendation No.411European Innovative Oncology Immunotherapy Project Seeking Chinese Partnerships (LMP2790)
Project ID: LMP2790
Project Description: Fully human afucosylated anti-GARP-TGFβ1 antibody (IgG1 antibody); dual-activity fully human afucosylated monoclonal antibody targeting GARP
Indications: GARP-positive solid tumors
Planned Phase 1: Non-small cell lung cancer, head and neck cancer, colorectal cancer
Planned Phase 2: Patients resistant/relapsed after immune checkpoint inhibitors
Collaboration Needs: Actively seeking global strategic partners for co-development, licensing, or equity investment; co-development is the preferred model
Company Profile, Project Background, Project Highlights......
Lingmed Newsletter Sep 2025In this month summary, Lingmed recommends
Lingmed asset recommendation 1：European Parkinson’s Disease Project with Innovative Mechanism
Lingmed asset recommendation 2：European Obesity & Anti-aging Project
The Aug 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Aug 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Innovative Project Recommendation No.409European Obesity & Anti-aging Project Seeking Partners in China (LMP1155)
Epidemiology of Sarcopenia, Obesity, and Duchenne Muscular Dystrophy (DMD)
Current Treatment Status for Sarcopenia and DMD
Recommendation from Lingmed— Sarcopenia / Obesity / COVID-19 / DMD Project
Lingmed Innovative Project Recommendation No.408European Innovative Mechanism – Parkinson’s Disease Project Seeks Chinese Collaboration (LMP2788)
Lingmed Newsletter August 2025In this month summary, Lingmed recommends
Lingmed asset recommendation：European Innovative Targeted Therapy for Inflammatory Bowel Disease
Lingmed monthly webinar Sep 2025: Advances in the Mechanism and Treatments of Parkinson's Disease
The July 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The July 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Innovative Project Recommendation No.406European Innovative Targeted Therapy for Inflammatory Bowel Disease Seeks Chinese Collaboration LMP2785
Project Code: LMP2785
Project Description: RIPK2 kinase inhibitor
Development Phase: Clinical Phase I/IIa
Indications: Gastrointestinal inflammatory diseases (e.g., Crohn’s disease, ulcerative colitis)， Advanced melanoma with secondary resistance to PD-1 therapy
Collaboration Needs: Actively seeking Chinese partners; collaboration mode negotiable.
Lingmed Newsletter July 2025In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Late-stage major depressive disorder project from EU
Lingmed asset recommendation 2：European Kinase inhibitor project with innovative target
Lingmed monthly webinar Sep 2025: Advances in the Mechanism and Treatments of Parkinson's Disease
The June 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The June 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.404A Phase III U.S./EU Project for Severe Depressive Disorder Seeking Chinese Partners
Epidemiology of Depression
Depression Treatment in China
Lingmed Recommended — Severe Depression Project ( Project Description, Clinical Stage, Indications, Partnership Goal, Company Profile, Background, Project Highlights)
Lingmed asset recommendation No.402European Innovative Targeted Kinase Inhibitor Project Seeking Partnerships in China
Project Number: LMP2785
Project Description: RIPK2 Kinase Inhibitor
Development Phase: Phase I/IIa clinical trials
Indications: Gastrointestinal inflammatory diseases (e.g., Crohn’s disease, ulcerative colitis)， Advanced melanoma with acquired resistance to PD-1 therapy
Partnership Needs: Actively seeking Chinese partners; collaboration models are negotiables
Lingmed Newsletter June 2025In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative acne vulgaris project from EU
Lingmed asset recommendation 2：European Kinase inhibitor project with innovative target
The May 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The May 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.401European Etiological Treatment Program for Follicular Skin Diseases Seeks Chinese Cooperation
Project Number: LMP1999
Project Description: Selective glutamyl endopeptidase
Project Phase : Topline results expected in Q3 2025 (for HS)
Indications: Moderate hidradenitis suppurativa (HS) and acne vulgaris (AV)
Project Needs: Actively seeking partners for co-development or out-licensing to advance clinical application and commercialization. The company is also interested in in-licensing dermatology-related assets to expand its product portfolio
Lingmed Newsletter May 2025In this month summary, Lingmed recommends
Lingmed asset recommendation：EU Phase II/III innovative serum eye drops for the treatment of dry eyes
Lingmed monthly webinar June 2025: Breakthrough & Innovation of Gastrointestinal Tumor drugs and Competitive Landscape Analysis
The Apr 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Apr 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter April 2025In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Paradigm-changing therapeutics for solid tumors——inducing Tertiary Lymphoid Structures (TLS)
Lingmed monthly webinar June 2025: Breakthrough & Innovation of Gastrointestinal Tumor drugs and Competitive Landscape Analysis
The Mar 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Mar 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.397Disruptive Immunotherapy for Solid Tumors – Induction of Tertiary Lymphoid Structures
Project Number: LMP2741
Project Description: An agonist of lymphotoxin beta receptor (LTBR); A bispecific antibody targeting fibroblast activation protein (FAP) and LTBR.
Project Phase: Preclinical, IND filing planned for 2026
Indication: Solid tumors
Partnership Opportunity: Actively seeking licensing partners in China. Multiple collaboration models are negotiable.
Company Overview：LMC5001702 is a UK-based innovative drug development company focused on studying fibroblast subpopulations and their interactions with the immune system. The company aims to restore normal immune function in cancer patients
Lingmed Newsletter March 2025In this month summary, Lingmed recommends
Lingmed Recommendation：BIO-Europe 2025 Spring Excellent Overseas Project Collection
Lingmed monthly webinar Apr 2025: Global development of innovative drugs for the treatment of chronic liver diseases
Lingmed Valuation Workshop in Sep: how to out license innovation to access to foreign investment
The Jan & Feb 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Feb 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.395Japanese Phase III Autologous Cell Therapy for Incontinence Seeking China Collaboration
Project Number: LMP0699
Project Description: Regenerative therapy — autologous skeletal muscle cell therapy for treating urgency fecal incontinence
Project Phase: Clinical Phase 3 (covering 10 European countries and Japan, Phase 3 in the US is currently under evaluation)
Indication: Urgency fecal incontinence
Project Needs: Actively seeking licensing partners in China, open for various collaboration models
Lingmed Newsletter Feb 2025In this month summary, Lingmed recommends
Lingmed asset recommendation：Rapid Al-based Genomic Testing to guide Early Cancer Treatment Decisions
Lingmed monthly webinar Mar 2025: Global development of innovative drugs for the treatment of chronic liver diseases
The Jan 2025 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jan 2025 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.393Rapid Al-based Genomic Testing to guide Early Cancer Treatment Decisions
Project Number: LMP2748
Project Description: Rapid Al-based Genomic Testing to guide Early Cancer Treatment Decisions
Project Stage: Early development
Indications: Lung cancer and other tumors
Project Requirements: Actively seeking global partners; various collaboration opportunities are available
Lingmed Newsletter Jan 2025In this month summary, Lingmed recommends
Lingmed asset recommendation：Innovative autoimmune disease project
Lingmed monthly webinar Feb 2025: New strategies and key mechanisms for hearing loss treatment
The Dec 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Dec 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.391Seeking Global Collaboration for Innovative Autoimmune Disease Project - LMP2712
Project Number: LMP2712
Project Description: Humanized Anti-CXCR6 Monoclonal Antibody
Project Stage: CMC/Preclinical
Indications: Primary indications are Primary Progressive Multiple Sclerosis (PPMS) and Vitiligo; other indications include Crohn's Disease, Ulcerative Colitis, Primary Biliary Cholangitis (PBC), and Myelin Oligodendrocyte Glycoprotein-Associated Diseases (MOGAD)
Project Requirements: Actively seeking global partners; various collaboration opportunities are available
Lingmed Newsletter Dec 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Best-in-Class Intestinal Inflammation Project
Lingmed asset recommendation 2：Novel Androgenetic Alopecia Project
Lingmed monthly webinar Feb 2025: New strategies and key mechanisms for hearing loss treatment
The Nov 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Nov 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.389Seeking Global Collaboration for a Novel Androgenetic Alopecia Project
Epidemiology of Androgenetic Alopecia
Treatment of Androgenetic Alopecia in China
Lingmed Project Recommendation: Androgenetic Alopecia Project (Project Description, Project Phase, Indication, Project Needs, Project Highlights, Company Profile)
Lingmed asset recommendation No.388Best-in-Class Intestinal Inflammation Project Seeking Global Collaboration
Epidemiology of Ulcerative Colitis
Treatment of Ulcerative Colitis in China
Lingmed Project Recommendation - Ulcerative Colitis Project
Lingmed Newsletter Nov 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative high-potential anti-inflammatory and anti-fibrotic project from EU
Lingmed asset recommendation 2：Novel regenerative therapeutics to cure neurological diseases by synaptic restoration
Lingmed monthly webinar Dec 2024: Boosting the chronic kidney disease sector, the obscure track enters a golden period
The Oct 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Oct 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.386European Innovation: High-Potential Anti-Inflammatory and Anti-Fibrotic Project Seeking Global Collaboration – LMP2706
Project Code: LMP2706
Project Description: Humanized anti-CCR2 IgG1 monocyte-depleting antibody; CC Chemokine Receptor 2 (CCR2)
Project Phase: Phase 1/1b clinical trials
Project Requirements: Seeking global partners/investors, with various collaboration opportunities available
Company Overview: LMC5001703 is a Swiss biotechnology company specializing in inflammation, autoimmunity, and fibrosis, with over 20 years of foundational research experience in inflammation and fibrosis
Lingmed Newsletter Oct 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative Oral Epilepsy drug from EU
Lingmed asset recommendation 2：U.S. Malignant Pleural Effusion Project
Lingmed monthly webinar Nov 2024: Analysis of drug targets and key pharmaceutical companies in pain therapeutic area
The Sep 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Sep 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.383U.S. Malignant Pleural Effusion Treatment Project Seeking Global Collaboration – LMP2711
Epidemiology of Malignant Pleural Effusion (MPE)
Treatment of Malignant Pleural Effusion in China
Lingmed Project Recommendation - Malignant Mesothelioma/Pleural Effusion Project
Lingmed asset recommendation No.381European Innovative Oral Epilepsy Medication Seeking Partnership in China – LMP2719
Epidemiology of Focal Epilepsy
Treatment of Focal Epilepsy in China
Lingmed Project Recommendation - Focal Epilepsy Project
Lingmed Newsletter Sep 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：High potential neuropathic pain program from EU
Lingmed asset recommendation 2：First in class androgenetic hair loss program
Lingmed monthly webinar Nov 2024: Analysis of drug targets and key pharmaceutical companies in pain therapeutic area
The Aug 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Aug 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.380European high-potential FLT3 inhibitor drug program seeks global collaboration - LMP1249
Epidemiology of neuropathic headache in the world & China
Neuropathic pain treatment in China
The issue of Lingmai’s Program Recommendations - Neuropathic Pain Program
Lingmed asset recommendation No.378First New Drug for Androgenetic Hair Loss Program – LMP1828
Global & Chinese Androgenetic Alopecia Epidemiology
Global Ranking of Androgenetic Alopecia Drugs
Treatment of androgenetic alopecia in China
This issue of Lingmai project recommendation - androgenetic alopecia project
Lingmed Newsletter Aug 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Solid Tumor ADC Program
Lingmed asset recommendation 2：Overseas Allergic Disease Program
Lingmed monthly webinar Sep 2024: Application of nano-antibodies in autoimmune diseases, are you ready?
The Jul 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jul 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.377Overseas Allergic Disease Program Seeks Global Collaboration – LMP1957
Item No.: LMP1957; LMP2662 Technology Platform
Project description
Project stage
Indication
Project requirements: LMP1957 looking for partner in Japan; LMP2662 technology platform global collaboration open for negotiation
Lingmed asset recommendation No.376Solid Tumor ADC Program Seeks Chinese Collaboration – LMP1983
Item number: LMP1983 linker; LMP1984
Project description: anti-B7-H3 dual oncolytic ADCs
Project stage: Preclinical
Indication: solid tumors
Project requirements: ADC platform technology and incubation projects looking for global collaboration, multiple collaborations negotiable
Lingmed Newsletter July 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative psoriasis program from EU
Lingmed asset recommendation 2：Innovative antibiotic resistance program from EU
Lingmed monthly webinar Sep 2024: Breakthrough and Innovation—Application of Regenerative Medicine in Neurological Diseases
The Jun 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jun 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.373Innovative Antibiotic Resistance Program in Europe Seeks Global Collaboration – LMP2661
Item No.: LMP2661
Project description: Metallo-β-lactamase inhibitor；β-lactamase inhibitor
Development Status: Phase 1 approved，planning to start in September，2024
Target Indications: Complicated Gram-negative bacterial infections，suitable for patients with complicated urinary tract, intra-abdominal, pulmonary, and bloodstream infections
Licensing Opportunities: LMC5001504 is looking for an opportunity to out-license LMP 2661 in Greater China.
Lingmed asset recommendation No.372European psoriasis nanobody drug program seeks global collaboration – LMP2663
Epidemiology of psoriasis in the world & China
Treatment of psoriasis in China
This issue of Lingmed's Program Recommendation - Mild to Moderate Psoriasis Nano Antibody Program
Lingmed Newsletter June 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Neurodegenerative Disease Program
Lingmed asset recommendation 2：U.S. HER2+ Gastric/Breast Cancer Bispecific Antibody Program
Lingmed monthly webinar Jul 2024: Breakthroughs & progress of antiepileptic drugs
The May 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The May 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.370U.S. HER2+ Gastric/Breast Cancer Dual Antibody Program Seeks Chinese Collaboration – LMP2658
Global & Chinese Gastric Cancer Epidemiology
Treatment of HER2+ gastric cancer in China
This issue of Lingmed’s Program Recommendation - HER2+ Gastric/Breast Cancer Program
Lingmed asset recommendation No.369Neurodegenerative Disease Program seeks global partnering – LMP1888
Global & Chinese Epidemiology of Alzheimer's Disease
Treatment of Alzheimer's disease in China
This issue of Lingmed’s Program Recommendation - Neurodegenerative Disease Program
Lingmed Newsletter May 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Novel MBL inhibitors reviving resistant antibiotics
Lingmed asset recommendation 2：Innovative drug delivery technology program from North American
Lingmed asset recommendation 3：IBD program with innovative target from EU
Lingmed monthly webinar Jun 2024: Breakthrough in the treatment of rare tumor malignant pleural mesothelioma
The Apr 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Apr 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.367North American Innovative Drug Delivery Technology Program seeks global partnering – LMP2660
Epidemiology of OA and EoE globally & in China
Treatment of OA and EoE in China
This issue of Lingmed’s project recommendation - OA and EoE project
Lingmed asset recommendation No.366Early Innovative Breakthroughs in New Targets for Chronic Inflammatory Bowel Disease IBD Seek Chinese Collaboration – LMP1951
Global & Chinese Inflammatory Bowel Disease Epidemiology
Treatment of inflammatory bowel disease in China
This issue of Lingmed's program recommendation - Inflammatory Bowel Disease program
Lingmed Newsletter April 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Rheumatoid Arthritis Program from EU
Lingmed asset recommendation 2：Rare chronic autoimmune disease program from North America
Lingmed monthly webinar May 2024: The past, present and future of antibiotic development
The Mar 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Mar 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.364North America rare chronic autoimmune disease program seeks global partnering – LMP2001
Global & Chinese System Sclerosis and FSGS Epidemiology
Treatment of System Sclerosis and FSGS in China
This issue of Lingmed's Project Recommendation - Dual Adaptation Rare Disease Project
Lingmed asset recommendation No.362European Rheumatoid Arthritis Program Seeks Global Collaboration – LMP1898
Global & Chinese Rheumatoid Arthritis Epidemiology
Global Rheumatoid Arthritis Drug Rankings
Treatment of rheumatoid arthritis in China
This issue of Lingmed’s program recommendation - rheumatoid arthritis program
Lingmed Newsletter March 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Immune checkpoint blockade therapy Adjuvant Program from EU
Lingmed asset recommendation 2：Peripheral T-Cell Lymphoma Program
Lingmed monthly webinar Apr 2024: Research and progress of CAR-T cell therapy for solid tumors [Register]
The Feb 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Feb 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.361Peripheral T-Cell Lymphoma Program Seeks Global Collaboration – LMP1997
Global & Chinese Epidemiology of Peripheral T-Cell Lymphoma
Treatment of peripheral T-cell lymphoma in China
This issue of Lingmed's Program Recommendation - Peripheral T-cell Lymphoma Program
Lingmed Newsletter Feb 2024In this month summary, Lingmed recommends
Lingmed asset recommendation：Respiratory diseases project from EU
Lingmed monthly webinar March 2024: Breakthrough & progress of novel targeted lipid-lowering drugs
The Jan 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jan 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Jan 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Acute ischemic stroke and post-stroke depression project with dual MoAs
Lingmed asset recommendation 2：Innovative Osteoarthritis project
Lingmed monthly webinar Feb 2024: Breakthrough & progress of novel targeted lipid-lowering drugs
The Dec 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Dec 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Dec 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：First-In-Class hypertrophic Scar & Keloids project
Lingmed asset recommendation 2：Oncology nuclear drug with innovative target
Lingmed monthly webinar Jan 2024: New blue ocean market—Novel weight loss drugs
The Nov 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Nov 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Nov 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative type 2 diabetes sustained-release project from US
Lingmed asset recommendation 2：Migraine Inhalation Project from EU
The Oct 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Oct 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Oct 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative oral preparation project for Age-related Macular Degeneration
Lingmed asset recommendation 2：Innovative respiratory disease project from EU
Lingmed monthly webinar Nov 2023: Research progress in the pathogenesis and treatment of depression
The Sep 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Sep 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Sep 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Long-acting Pulmonary Arterial Hypertension Program from EU
Lingmed asset recommendation 2：Long-acting Preloaded Prostate Cancer program from EU
Lingmed monthly webinar Oct 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
The Aug 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Aug 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.344European Long-Term Pulmonary Arterial Hypertension Program seeks global partnering
Global and China Pulmonary Hypertension Epidemiology
Global Pulmonary Arterial Hypertension Drug Ranking
Treatment of Pulmonary Arterial Hypertension in China
Lingmed innovative asset recommendation –Pulmonary Arterial Hypertension
Lingmed asset recommendation No.343European Long-acting Preloaded Prostate Cancer program seeks global partnering - LMP1855
Global and China Prostate Cancer Epidemiology
Global Prostate Cancer Drug Ranking
Treatment of Prostate Cancer in China
Lingmed innovative asset recommendation – Prostate Cancer program
Lingmed Newsletter Aug 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria
Lingmed asset recommendation 2：Innovative Chronic Kidney Disease program
Lingmed monthly webinar Sep 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
The 12th Pharma - Biotech Product and Company Valuation Register
The July 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The July 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.341Innovative Chronic Kidney Disease program seeks a global partner
Global and China Chronic Kidney Disease Epidemiology
Global Chronic Kidney Disease Drug Ranking
Treatment of Chronic Kidney Disease in China
Lingmed innovative asset recommendation – Chronic Kidney Disease project
Lingmed asset recommendation No.340Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria?
Global and Chinese Epidemiology of Chronic Spontaneous Urticaria
Global and Chinese Urticaria Drug Ranking
Treatment of Chronic Spontaneous Urticaria in China
Lingmed innovative asset recommendation – Chronic Spontaneous Urticaria Program
Lingmed asset recommendation No.338China's rising stars of innovation - portable inhalation device for pulmonary hypertension - Patent global licensing opportunity LMP1853
Medical NO gas therapy has wide application potential
Integrating more than 60 patents to establish a solid NO generation molecular technology platform
Potential indications and product forms
Portable nitric oxide inhalation therapy device
Product features
The main uses of the LMP1853 portable inhaled nitric oxide therapy device
Cooperation models
Lingmed Newsletter July 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative U.S. Anesthesia Reversal Agent program
Lingmed asset recommendation 2：Oversea topical skin disease innovation
Lingmed monthly webinar Aug 2023: Development progress of new drug development for skin diseases Register
The 12th Pharma - Biotech Product and Company Valuation Register
The Jun 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jun 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.336Oversea topical skin disease innovations
Global and Chinese Acne Epidemiology
Global and Chinese Acne Drug List
Chinese acne treatment
Lingmed innovative asset recommendation – Skin Disease Program
Lingmed asset recommendation No.336Innovative U.S. Anesthesia Reversal Agent program seeks partnering into China market
Global Epidemiology of Delayed Awakening from Anesthesia
Global & Chinese Delayed Awakening from Anesthesia Drug Ranking
Chinese Guidelines for Treatment of Delayed Awakening from Anesthesia
Lingmed innovative asset recommendation – Anesthesia Reversal Agent Program
Lingmed Newsletter June 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：New breakthrough in innovative target for rare blood diseases
Lingmed asset recommendation 2：Overseas Primary Sclerosing Cholangitis program
Lingmed monthly webinar Jul 2023: Chronic Pain Market Development Potential and Market Size Register
The 12th Pharma - Biotech Product and Company Valuation Register
The May 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The May 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.334Overseas primary sclerosing cholangitis program seeks partnering into China market
Global and Chinese PSC Epidemiology
Global & Chinese PSC Drug Ranking
Chinese guidelines for diagnosis and treatment of PSC
Lingmed innovative asset recommendation – Primary Sclerosing Cholangitis Program
Lingmed asset recommendation No.333New breakthrough in innovative target for rare blood diseases - LMP1421
Global PNH Epidemiology
Global & Chinese PNH Drug Ranking
Chinese guidelines for diagnosis and treatment of PNH
Lingmed innovative asset recommendation – PHN Program
Lingmed Newsletter May 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Overseas First-Line Therapy Program for Pancreatic Cancer
Lingmed asset recommendation 2：U.S. Innovative Oncology Program
Lingmed monthly webinar Jun 2023: Prospects for drug development of heterologous antibodies Register
The Apr 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Apr 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.331Oncology innovation from US biotech seeks partnering into China market
Global epidemiology of AML/ALL, DLBCL, MM and other tumors
Global & Chinese AML/ALL Drug Ranking
China AML/ALL diagnosis and treatment guidelines
Lingmed innovative asset recommendation – Multi-tumor Indication Program
Lingmed asset recommendation No.328Overseas First-Line Therapy Program for Pancreatic Cancer Seeks Chinese Collaboration
Global & Chinese Pancreatic Cancer Epidemiology
Global Pancreatic Cancer Drug Ranking
China Pancreatic Cancer Treatment Guidelines (2022)
Lingmed innovative asset recommendation – Pancreatic Cancer and Pulmonary Fibrosis Program
Lingmed Newsletter April 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Phase III Tenosynovial Giant Cell Tumor Program from EU
Lingmed asset recommendation 2：U.S. Innovative Respiratory Infection Program
Lingmed monthly webinar May 2023: R&D pattern analysis of novel drug delivery systems Register
The Mar 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Mar 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.329U.S. Innovative Respiratory Infection Program Seeks Chinese Collaboration
Company Profile
Respiratory Infection Program LMP1857 Introduction
LMP1857 potential applications
LMP1857 patent status
LMP1857 Cooperation Opportunities
Lingmed asset recommendation No.327European Phase III Tenosynovial Giant Cell Tumor Program Seeks Chinese Collaboration
Global & Chinese Epidemiology of Tenosynovial Giant Cell Tumor
Global Tenosynovial Giant Cell Tumor Drug Ranking
Guidelines for Diagnosis and Treatment of Giant Cell Tumor of the Tendon Sheath in China
Lingmed innovative asset recommendation – Tenosynovial giant cell tumor program
If you are interested in Lingmed historical achieved reports, please click here
Confirm your details on form below to download this report
